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Abstract
Background—An algorithm to classify heart failure (HF) endpoints inclusive of contemporary
measures of biomarkers and echocardiography was recently proposed by an international expert
panel. Our objective was to assess agreement of HF classification by this contemporaneous
algorithm with that by a standardized physician reviewer panel, when applied to data abstracted
from community-based hospital records.
Methods and Results—During 2005-2007, all hospitalizations were identified from four U.S.
communities under surveillance as part of the Atherosclerosis Risk in Communities (ARIC) study.
Potential HF hospitalizations were sampled by ICD discharge codes and demographics from men
and women aged 55 years and older. The HF classification algorithm was automated and applied
to 2,729 (N=13,854 weighted hospitalizations) hospitalizations in which either BNP measures or
ejection fraction were documented (mean age 75 years). There were 1,403 (54%, N=7,534
weighted) events classified as acute, decompensated HF (ADHF) by the automated algorithm, and
1,748 (68%, N=9,276 weighted) such events by the ARIC reviewer panel. The chance-corrected
agreement between ADHF by physician reviewer panel and the automated algorithm was
moderate (Kappa=0.39). Sensitivity and specificity of the automated algorithm with ARIC
reviewer panel as the referent standard was 0.68 (95% CI, 0.67 - 0.69), and 0.75 (95% CI, 0.74 -
0.76), respectively.
Conclusions—Although the automated classification improved efficiency and decreased costs,
its accuracy in classifying HF hospitalizations was modest compared to a standardized physician
reviewer panel.
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Clinical research and epidemiologic studies of heart failure (HF) have been hindered by the
lack of a consensus definition of HF as an event or endpoint that is valid, repeatable and
cost-effective 1-4. The pleomorphic nature of the HF syndrome contributes to the difficulty
in defining and classifying HF. HF manifestations can be vague, as well as shared with other
conditions that are often comorbid with HF, such as respiratory and renal disease5. Thus, the
current gold standard for HF classification is expert review of medical records and
adjudication, 6, 7 although classification of HF by an expert reviewer panel is subject to
more misclassification than for events such as myocardial infarction and stroke. A
standardized and repeatable event review by a reviewer panel is expensive and time
consuming, and thus not practical for most studies, and further difficulties include the use of
diverse classification schema. Although the Framingham, modified Boston and NHANES
classification schema are widely used, their relevance to contemporary classifications of HF
events is questionable4, since most extant HF classification schema were created prior to the
clinical use of biomarkers and cardiac imaging in HF diagnosis and care. Furthermore, they
largely do not consider whether an HF event is new, or decompensated2.
To develop a contemporary definition of HF, an international group of cardiovascular
clinical trialists, biostatisticians, National Institutes of Health (NIH) scientists, regulators,
and pharmaceutical industry scientists published recommendations for an updated
classification of HF for clinical trials and observational studies of HF4. Extending prior HF
classifications, biomarker and echocardiographic information was included, and the
distinction between 3 types of HF events was emphasized (Table 1). The 3 types of HF
events include: those with a new diagnosis, a new event without prior HF, or a new event
with history of HF. The first two groups largely differ by severity and setting of
presentation. Henceforth we refer to this expert panel as the Cardiovascular Clinical Trialists
(CCT) Workshop4 and to their proposed HF event definition as the HF algorithm. As far as
we know this algorithm has yet to be implemented or evaluated, therefore we
operationalized and automated a modified version of the HF algorithm proposed by the CCT
for hospitalized events of HF regardless of history of HF. We examined its performance
characteristics on data abstracted by trained personnel from medical records of a population-
based sample of HF hospitalizations in four U.S communities. Hospitalizations included all
men and women aged 55 years and older with ICD-coded discharge diagnoses related to HF
during 2005-2007 in these areas8. We tested the concordance of this automated HF
classification algorithm with an established panel of standardized physician reviewers of the
Atherosclerosis Risk in Communities (ARIC) study8.
Methods
Automated Classification of HF
To examine the applicability and usefulness of the HF algorithm in population settings, we
ascertained the HF classification criteria items from hospital medical records, and thus
applicable to clinical research studies using electronic health records (EHR) or
epidemiologic surveillance studies. Accordingly we deferred classification of HF according
to history of HF and instead examined performance of a modified version of the HF
algorithm that does not consider HF history. We modified the criteria identified by the CCT
as “HF as a new event,” to achieve wider interest and applicability (Table 1). If a
classification algorithm performs sufficiently well, the distinction of events according to
their prevalent or incident nature is typically done as an analytic step and not as an event
classification category. Furthermore, we did not include death due to HF. See Supplemental
Methods Section for details. Given that the purpose of this study is to test the automated
algorithm in the real world setting of hospital medical records, there was neither an
echocardiogram reading center nor a central laboratory for the measurement of BNP.
Hospital records that made no reference to measures of either ejection fraction or BNP/NT
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pro-BNP were considered not indicative of HF for the missing measure. Records missing
both BNP and ejection fraction measures were excluded to preserve the validity of the
comparison.
Study Population
The Atherosclerosis Risk in Communities (ARIC) study has conducted population-based
retrospective surveillance for coronary heart disease since 19878. HF has been a target for
community surveillance in ARIC since 2005, based on a sample of hospital discharges in
four geographically defined areas in the U.S., for all residents age 55 years and older 9.
Because ARIC began automatically classifying some of the eligible hospitalizations in 2008,
we limit this analysis to 2005-2007. The four ARIC study areas are the city of Jackson,
Mississippi; Washington County, Maryland; eight northwestern suburbs of Minneapolis,
Minnesota; and Forsyth County, North Carolina. In 2005, these four regions had an overall
population of 177,000 ages 55 and older. Non-black and non-white race groups are excluded
due to small numbers. The institutional review boards from each study site approved the
ARIC study.
Ascertainment of Hospitalizations for Heart Failure
Annually lists of hospital discharges meeting a target list of International Classification of
Disease 9thRevision-Clinical Modification (ICD-9-CM) codes were obtained from the
hospitals in the 4 ARIC communities (31 hospitals in 2005). See Supplemental Table 1 for a
list of targeted HF ICD-9-CM codes. For 91% of the sample, a ‘428’ for “congestive HF”
was listed as one of the codes. For all community residents aged 55 years and older,
hospitalizations were sampled using stratified probabilistic sampling by HF ICD-9-CM
code, age, gender, race and area of residence in the community. Sampling probabilities by
strata were selected to optimize variance estimates for HF event rates within strata, and
based on the pre-specified maximum number of events planned for data abstraction9. Results
are weighted for these sampling probabilities to maintain population estimates for the
distribution of ICD codes and other factors that may affect concordance.
Abstraction and Classification of Heart Failure Events
Medical records were abstracted by trained study personnel following a standardized
protocol. Each record was first abstracted to answer 6 screening questions for ADHF; if any
of the answers were positive a full abstraction ensued. The 6 screening items included
mention of any of the following: increasing or new onset shortness of breath, peripheral
edema, paroxysmal dyspnea, orthopnea, hypoxia, or HF as a cause for hospitalization. Of all
records with a HF ICD code, 36% did not meet the screening criteria and were not
abstracted in full, and were not included in these analyses. A separate analysis examined the
effect of this efficiency-based screening in a subset of 797 medical records, based on a full
data abstraction for medical records that would have been screened out. We found that 48%
(N=386) had either BNP or a measure of ejection fraction and thus would have qualified for
analysis. Of the 386 medical records with biomarker or imaging information, 11.7% were
found to have definite or possible ADHF per ARIC reviewer panel. In comparison, 68% of
the records fully abstracted for this study had definite or possible HF by ARIC reviewer
panel. Thus, screening prior to full record abstraction was effective in yielding a low number
of false negatives.
Full record abstraction using the heart failure abstraction form comprehensively
incorporated the pertinent elements for classification of HF, and history of comorbid
conditions as described previously (abstraction form available at http://drupal.cscc.unc.edu/
aric/hf-forms).9 A computer–based classification was applied to the abstracted data to arrive
at the appropriate classification for the CCT automated algorithm (Table 1, and Table 2).
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Secondarily, conventional HF criteria (Framingham10, Boston11, NHANES12, and
Gothenburg13) were also defined from abstracted data (results are presented in the
Supplement).9 Eligible hospitalizations were independently reviewed by one or two trained
physician reviewer (s) with resolution of disagreements by an adjudicator. Physicians
followed ARIC HF classification guidelines when evaluating medical records, and applied
judgment to arrive at a classification of definite acute decompensated HF (ADHF), possible
ADHF, chronic HF, HF unlikely, or unclassifiable9. Here definite and possible ADHF have
been combined into a single category of ‘ADHF present’, and the other 3 categories have
been combined as ‘ADHF absent’.
Classification of Heart Failure Events in ARIC
The ARIC classification guidelines have been described 9. Classification of definite acute
decompensated HF (ADHF) required clear evidence of HF with active decompensation, and
the presence of HF with certainty as to the cause of the presentation. Possible acute
decompensated HF included criteria similar to definite ADHF, without as much certainty
that HF is the cause of the presentation. A classification of chronic HF applied to a history
of HF that was not decompensated.
Statistical Analysis
All estimates were weighted to account for the sampling design and to maintain the
population distribution of ICD codes and other factors that may affect concordance. We
cannot reliably link hospitalizations to identify repeat events, therefore all hospitalizations
are assumed to be independent. The positive and negative agreement, the kappa coefficient,
and the prevalence and bias adjusted Kappa (PABAK) were calculated relating the
automated algorithm to the ARIC reviewer panel classifications. The prevalence and bias
adjusted kappa (PABAK) were calculated since the prevalences of positive and negative
tests were not balanced, which can result in a Kappa with low reliability even when
observed agreement is good14, 15. Measures of validity were calculated for the components
of the automated algorithm individually and for the schema overall. Positive and negative
predictive values were calculated for several different disease prevalences16. Formulas
specified in table footnotes.
Results
There were 2,729 sampled hospitalizations eligible for review during 2005-2007, which
resulted in 15,484 events after applying weights to account for sampling fractions. The
tables and their discussion refer to the weighted number of events. Of these, 10.5%
(N=1,630 weighted) were missing BNP measures and ejection fraction and thus were
excluded, leaving a sample of 13,854 for this analysis. Of those classified as ADHF by the
automated algorithm, 85% (69% + 16%) were classified as definite or possible ADHF by the
ARIC reviewer panel (See Table 3, with unweighted numbers in Supplemental Table 2). Of
those classified as not having ADHF by the automated algorithm, 47% were classified as
ADHF and 20% as chronic HF by ARIC panel review.
Overall, characteristics of patients with ADHF per the ARIC reviewer panel and the
automated algorithm did not differ appreciably (Supplemental Table 3). In each group the
mean age was 75 years, with 51-52% women, and 28-30% African Americans.
Hypertension (83%) and diabetes (46-48%) were common for both groups.
Table 4 shows the characteristics of those classified with agreement and disagreement when
comparing the automated algorithm to the ARIC reviewer panel. The overt differences
between groups were few, but informative. The frequency of end stage renal disease was
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highest (34%) in those without ADHF by both criteria, and then next highest (21%) for
those with ADHF per the automated algorithm, and not by ARIC reviewer panel. The mean
levels of BNP and NT-proBNP were visibly lower in the group classified as ADHF absent
by the automated algorithm but present according to the ARIC reviewer panel. Those given
diuretics were more likely to be classified with agreement as ADHF present (85% of those
correctly classified, as compared to 55-69% for those misclassified).
Table 5 shows measures of test validity calculated for the automated algorithm and its
components, compared to the ARIC reviewer panel as a referent. The sensitivity was 0.68
and specificity 0.75 for the automated algorithm overall, with a positive predictive value of
0.85 and negative predictive value of 0.53. The prevalence of ADHF was 68% in this
enriched sample of hospitalized events. Since predictive values differ according to
prevalences we calculated predictive values for lower disease prevalences (e.g., for a
prevalence of HF in the sample of 25%, the PPV = 0.48, and NPV = 0.88). As for the
individual components of the algorithm, notably, elevated BNP or NT-proBNP taken in
isolation showed comparable levels of validity to the algorithm overall (a sensitivity of 0.78
and specificity of 0.64), although this represents a smaller group (81% of the sampled
hospital records) with non-missing biomarkers.
In Table 6 (also in Supplemental Table 4), the agreement and validity statistics for ADHF by
the ARIC reviewer panel were compared to the automated algorithm. The prevalence and
bias adjustment of Kappa (PABAK) does not suggest a large influence of internal imbalance
in these data on the Kappa statistic.
Discussion
We assessed the applicability and classification properties of an algorithm proposed for the
classification of HF endpoints in clinical trials or observational studies that incorporates
diagnostic tools routinely used in current medical practice. We evaluated the performance of
this algorithm in the setting of hospitalizations sampled from a large number of hospitals
from four regions of the US that participate in an NHLBI-sponsored epidemiology study of
HF. The evaluation of an automated HF algorithm that incorporates biomarkers and
echocardiographic measures is novel in the context of a large, population-based sample of
hospitalizations, and is notable for its scope and generalizability. In addition to signs and
symptoms as elements of the HF syndrome, the availability of echocardiographic imaging
and biomarker information abstracted from records generated in the course of routine
medical care indicate that an application of an automated algorithm is feasible under these
circumstances, and was successful. We found that 89.5% of hospital medical records
sampled during the period 2005-2007 contained either BNP/NT-proBNP or
echocardiographic measures suitable for use in applying this algorithm. Further, by adding
detail and some modifications to the definitions published by Zannad et al4, we were able to
operationalize an algorithmic definition for HF. The ability to apply an automated algorithm
to real-world settings and EHR highlights the potential efficiencies in the classification of
HF events for research and administrative applications based on hospital medical records.
To our knowledge this is the first study to assess the classification performance of this
algorithm and its validity relative to a standardized HF classification method by a panel of
physician reviewers. Since HF is a clinical syndrome for which there is no consensus
definition, its classification is difficult. Additional complexity is added by the episodes of
acute decompensation that characterize HF. This study focused on an accurate and
reproducible algorithmic classification of ADHF. Based on 15,484 (weighted)
hospitalizations sampled during 2005-2007 from all hospitals that serve the residents of four
regions in the U.S., we found modest agreement between ADHF defined by the automated
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algorithm and by the ARIC reviewer panel (Kappa of 0.39, PABAK of 0.41). Chance
adjusted agreement, as measured by Cohen's Kappa was slightly higher here than agreement
between existing HF criteria and the ARIC reviewer panel as shown in a prior publication
(Framingham K=0.32, Modified Boston K=0.18)9. Given that the ARIC HF panel reviewers
considered BNP measures and echocardiography findings in classifying HF events, we
expected the automated algorithm (which includes criteria elements for these measures) to
have better agreement with ARIC's ADHF than the other schema considered which do not
consider these measures. In addition, existing HF schemas do not distinguish acute
decompensated HF from chronic HF, whereas the automated algorithm and the ARIC
reviewer classification do.
Employing ARIC's classification of ADHF as a referent standard, we found a sensitivity of
0.68 (95% CI, 0.67-0.69) for the automated algorithm, i.e., 68% of those with ADHF by the
ARIC reviewer panel (reference standard) were also found to have ADHF per automated
algorithm. Thus, 32% of those with ADHF were missed as false negatives applying the
automated algorithm. Specificity was estimated as 0.75 (95% CI, 0.74-0.76), implying that
75% of those who did not have ADHF by the reference standard also were found not to have
ADHF by the automated algorithm (true negatives), and 25% of those without HF were false
positives according to the automated algorithm. Using the ARIC reviewer panel as the
referent standard, the automated algorithm performed with higher specificity, and lower
sensitivity compared to other commonly used HF classification schema (Supplemental Table
5). The automated algorithm did not perform at higher validity on both sensitivity and
specificity when compared to the existing criteria, thus the relative value of sensitivity and
specificity, and the cost of each type of misclassification need to be considered in the
particular setting for which the classification of HF events is needed. The varied settings in
which HF classification may be applied include the identification of potential participants
with HF for a clinical trial, the identification of HF as an adverse events, and case-finding
efforts that search through large databanks of electronic medical records.
Overall the automated algorithm had a better balance of sensitivity and specificity than any
one individual component. The overall balance between sensitivity and specificity for the
automated algorithm was closest to that for the BNP levels as individual criterion element,
although the biomarkers achieved higher sensitivity than specificity. Of note, hospital
records containing BNP measures may reflect a different spectrum of disease or patient
population than the overall sample of hospitalized residents of these study areas. Since
biomarkers and echocardiographic measurements may be performed differentially in clinical
settings, the automated algorithm is not likely to perform as well in circumstances where
these measures would not be obtained routinely. Furthermore, our focus is the performance
of this algorithm in real world settings, and thus we did not limit the analysis to those with
both measures. We would expect different results in a population that had both biomarkers
and echocardiogram measures performed during a hospitalization, but both of these
measures are not routinely obtained in HF hospitalizations.
Our study material included only hospitalizations lasting at least 24 hours. This may be a
limitation in that milder cases of ADHF that could have been managed in the emergency
department or admitted overnight to observation care would mostly be missed here. It is
therefore unknown how the automated HF classification algorithm performs on data that
include milder forms of ADHF. An additional limitation is that eligible hospital records with
a qualifying ICD code for HF were abstracted only in part when the record did not include
reference to increasing, or new onset shortness of breath, peripheral edema, paroxysmal
dyspnea, orthopnea, hypoxia or documentation that the reason for the event was HF. Across
all hospitals included in this study 36% of medical records did not meet the above screening
criteria, and were not abstracted in full. A calibration sub-study of hospital records that did
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not meet these inclusion criteria and were fully abstracted (N = 797) found that only 48% of
those records that were screened out would have met criteria for classification using this
automated algorithm, and that only 11.7% of those were identified as ADHF by ARIC.
Thus, the impact of the criterion to select hospital records eligible for full abstraction on the
results reported here is therefore quite small. Lastly, as expected in the setting of
community-based hospitals, the biomarker assays and echocardiography measurements were
not interpreted in a central reading center or laboratory; therefore, some (unmeasured)
variability is to be expected. Further studies should assess this algorithm in other settings,
such as in a clinical trial, in which the goal is usually to define HF endpoints of ADHF in
those known to have HF. Although centrally analyzed biomarker levels and centrally read
imaging may be available from most clinical trials at baseline, it is relevant to note that
many large multi-center clinical trials with HF hospitalization as endpoints are also
dependent on the clinical infrastructure for imaging and biomarker measures, in place of a
centralized processing of these measures4.
Among the strengths of this report are the novelty of the application of an automated
algorithm for the classification of HF in a population-based setting and the rigorous
evaluation of its performance characteristics in contemporaneous hospital-based practice.
Additional strengths include the use of a large database of hospital records sampled to
represent hospitalizations among the residents of four regions, and their abstraction by
trained study personnel following a standardized protocol. Since as of yet, there is no
agreed-upon gold standard to classify HF, a systematic physician review and classification
according to standardized criteria represents the best available gold standard. Our reliance
on a comprehensive and standardized protocol for the classification of ADHF that included a
panel of calibrated physician reviewers adds strengths to the information reported here.
In conclusion, we were able to apply an algorithm recommended by an international panel of
experts for the classification of HF to medical records sampled from diverse hospitals in
geographically well-defined areas in the U.S., and to automate this algorithm efficiently for
use on data abstracted from records by trained personnel. The validity (accuracy) of the
automated algorithm for ADHF was moderate at best compared to the classification of
ADHF by ARIC's reviewer panel, although the agreement and specificity for the automated
algorithm were greater than for the commonly used HF criteria that do not account for
contemporary measures of BNP or echocardiography (Supplemental Table 5) . The
development of HF classification criteria that agree with the highest reference standard of
physician reviewer classification, and their evaluation in the setting of medical practice, are
priorities for clinical and population based research. If such an algorithm is used to classify
all hospital admissions rather than those with high prior odds of HF as done in this study,
then the concordance will be extremely high as most records will not have HF by either
criterion.
Diastolic dysfunction, a common finding in the elderly population without HF, does not
contribute much to the ability to classify HF. Unlike with systolic dysfunction, the CCT
algorithm requires that those with diastolic dysfunction must also have moderately elevated
biomarkers to meet criteria for ADHF. It is possible that uniform measurements of diastolic
parameters, which are not often reported in clinical echocardiograms, and research to define
the appropriate set of parameters to best define diastolic dysfunction may improve its utility
for classification. The ability to classify ADHF with an up-to-date, automated classification
algorithm and evaluate its performance characteristics is a critical step toward the
establishment and standardized application of consensus criteria for HF. Advantages derived
from their use would apply to the utilization of large medical records database resources, as
well as efficiencies in time and costs.
Loehr et al. Page 7














Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank the staff and participants of the ARIC study for their important contributions.
Sources of Funding: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study
supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
HHSN268201100011C, and HHSN268201100012C).
References
1. Vasan RS, Levy D. Defining diastolic heart failure: A call for standardized diagnostic criteria.
Circulation. 2000; 101:2118–2121. [PubMed: 10790356]
2. Mosterd A, Deckers JW, Hoes AW, Nederpel A, Smeets A, Linker DT, Grobbee DE. Classification
of heart failure in population based research: An assessment of six heart failure scores. European
journal of epidemiology. 1997; 13:491–502. [PubMed: 9258559]
3. Di Bari M, Pozzi C, Cavallini MC, Innocenti F, Baldereschi G, De Alfieri W, Antonini E, Pini R,
Masotti G, Marchionni N. The diagnosis of heart failure in the community. Comparative validation
of four sets of criteria in unselected older adults: The icare dicomano study. Journal of the American
College of Cardiology. 2004; 44:1601–1608. [PubMed: 15489092]
4. Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, Torp-Pedersen C, Kirwan BA,
Follath F. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical
trials: The need for a consensus definition. European heart journal. 2008; 29:413–421. [PubMed:
18245122]
5. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive
pulmonary disease: An ignored combination? Eur J Heart Fail. 2006; 8:706–711. [PubMed:
16531114]
6. Heckbert SR, Kooperberg C, Safford MM, Psaty BM, Hsia J, McTiernan A, Gaziano JM, Frishman
WH, Curb JD. Comparison of self-report, hospital discharge codes, and adjudication of
cardiovascular events in the women's health initiative. Am J Epidemiol. 2004; 160:1152–1158.
[PubMed: 15583367]
7. Schellenbaum GD, Heckbert SR, Smith NL, Rea TD, Lumley T, Kitzman DW, Roger VL, Taylor
HA, Psaty BM. Congestive heart failure incidence and prognosis: Case identification using central
adjudication versus hospital discharge diagnoses. Annals of epidemiology. 2006; 16:115–122.
[PubMed: 15964203]
8. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD,
Tyroler HA. Community surveillance of coronary heart disease in the atherosclerosis risk in
communities (aric) study: Methods and initial two years' experience. Journal of clinical
epidemiology. 1996; 49:223–233. [PubMed: 8606324]
9. Rosamond WD, Chang PP, Baggett C, Johnson A, Bertoni AG, Shahar E, Deswal A, Heiss G,
Chambless LE. Classification of heart failure in the atherosclerosis risk in communities (aric) study:
A comparison of diagnostic criteria. Circ Heart Fail. 2012; 5:152–159. [PubMed: 22271752]
10. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive
heart failure in framingham heart study subjects. Circulation. 1993; 88:107–115. [PubMed:
8319323]
11. Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of physicians' reasons for
prescribing long-term digitalis therapy in outpatients. J Chronic Dis. 1985; 38:733–739. [PubMed:
4030999]
12. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive
heart failure in the united states. Journal of the American College of Cardiology. 1992; 20:301–
306. [PubMed: 1634664]
Loehr et al. Page 8













13. Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L, Svardsudd K. Cardiac and
pulmonary causes of dyspnoea--validation of a scoring test for clinical-epidemiological use: The
study of men born in 1913. European heart journal. 1987; 8:1007–1014. [PubMed: 3665952]
14. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. Journal of clinical epidemiology. 1993;
46:423–429. [PubMed: 8501467]
15. Cunningham, M. In: Inc. SI. , editor. More than just the kappa coefficient: A program to fully
characterize inter-rater reliability between two raters; Proceedings of the sas®global forum 2009
conference; Cary, NC. SAS Institute Inc.; 2009.
16. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ. 1994; 309:102. [PubMed:
8038641]
Loehr et al. Page 9

























Loehr et al. Page 10
Table 1
Cardiovascular Clinical Trialists' (CCT) definitions of heart failure for a new diagnosis,
new event, or recurrent event, followed by the adapted automated algorithm used in this
study (adapted based on the highlighted column)
1. New onset HF as a
diagnosis 2. HF as a new event
* 3. HF as an event Adapted automated algorithm†
History of HF No No Yes Yes or No
HF Signs and Symptoms +/-* Yes Yes Yes
Treatment for HF Yes* Yes Yes Yes
Imaging and biomarkers Yes Yes No Yes
*
For new onset HF as a diagnosis, treatment must be for HF symptoms, but there is not requirement that there be at least 2 symptoms present as
with the other 2 categories
†
Modified to include all 4 categories of “HF as a new event” (column 2) to include those with or without a prior history of HF documented in the
medical. Outpatient visits are not included in the study sample.
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Table 2
Adapted automated Cardiovascular Clinical Trialists' (CCT) algorithm for a hospitalized event of ADHF
(either new or recurrent). All 3 criteria elements must be met to define a heart failure event.
1) Signs and Symptoms, presence of ≥ 2 HF signs or symptoms among the following:
shortness of breath or dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, fatigue or reduced exercise tolerance, pulmonary edema,
rales, peripheral edema, JVD, S3, hepatojugular reflux, altered hemodynamics, cardiomegaly
2) Treatment
Initiation or increase in treatment with loop diuretics, or IV vasoactive agents. The automated algorithm' criteria specifies that this treatment
should be specifically for the above symptoms, however our abstraction only confirms that such treatment was provided during this
hospitalization
3) Biomarkers and Imaging, at least one of the following:
a. Elevated BNP (≥400 ng/L*) or elevated NT-proBNP using age defined cutpoints†
OR
b. LVEF < 40%
OR
c. Moderately elevated BNP (100-400 ng/L) or NT-proBNP† (defined as < age cutpoints) AND documentation of LVEF < 40% or
diastolic dysfunction
*
Note: SI units shown of ng/L = pg/ml.
†
Elevated NT-proBNP defined as: if <50years then ≥ 450 ng/L; if 50-75 years then ≥ 900 ng/L; if 75 years then ≥ 1800 ng/L. Moderately elevated
NT pro-BNP defined with 300 ng/L as the bottom cutpoint for all age groups: if <50years then 300-450 ng/L; if 50-75 years then 300-900 ng/L; if
75 years then 300-1800 ng/L.
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Table 6
Measures of agreement and validity for the classification of acute decompensated heart
failure (ADHF) using the automated algorithm as compared with a referent standard of
the ARIC reviewer panel (N=13,855*)
ARIC Reviewer Panel
ADHF present, N ADHF absent, N
Automated Algorithm, ADHF present 6,411 1,123




Cohen's Kappa 0.39 (0.38, 0.41)
Prevalence Adjusted Bias Adjusted Kappa (PABAK) 0.41
Prevalence Index 0.22
Bias Index 0.13
Measures of Validity with ARIC Reviewer Panel as Referent Standard
Sensitivity 0.68 (0.67, 0.69)
Specificity 0.75 (0.74, 0.76)
Positive predictive value 0.85 (0.84, 0.86)
Negative Predictive Value 0.53 (0.52, 0.54)
Likelihood Ratio positive 2.72 (2.59, 2.87)
Likelihood Ratio negative 0.43 (0.41, 0.44)
*
All numbers were weighted to account for sampling fractions
Formulas used in calculations: Using a 2 × 2 table with ARIC as the gold standard, a−d are defined as follows: a = + ARIC, + automated algorithm,
b= − ARIC, + Automated algorithm, c = +ARIC, − Automated algorithm, and d = −ARIC, −Automated algorithm
Sensitivity = a/a+c; specificity = d/b+d; PPV = a/(a+ b); NPV = d/c+d.
Positive Likelihood Ratio= (sensitivity)/(1−specificity) = TP/FP
Negative Likelihood Ratio= (1−sensitivity)/(specificity) = FN/TN
PABAK formula = 2 (observed agreement −1). The observed agreement = (a+d)/N The prevalence of ADHF by ARIC = 9376/13854 = 0.68
Circ Heart Fail. Author manuscript; available in PMC 2014 July 01.
